Back to top
more

Insmed (INSM)

(Delayed Data from NSDQ)

$109.30 USD

109.30
3,319,625

-1.96 (-1.76%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $109.36 +0.06 (0.05%) 5:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

New Strong Sell Stocks for October 29th

by Zacks Equity Research

IBIO, POST, INSM, DVA, and BSET have been added to the Zacks Rank #5 (Strong Sell) List on October 29, 2021.

Zacks Equity Research

Insmed (INSM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -15.66% and -2.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Insmed (INSM) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Insmed (INSM) has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Equity Research

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -10.59% and 4.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Insmed (INSM) Q2 Earnings Expected to Decline

by Zacks Equity Research

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why Insmed (INSM) is Poised for a Turnaround After Losing 19.5% in 4 Weeks

by Zacks Equity Research

Insmed (INSM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of 2.20% and 1.09%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline

by Zacks Equity Research

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Insmed (INSM) Starts Dosing in Phase III Bronchiectasis Study

by Zacks Equity Research

Insmed (INSM) doses the first patient in the phase III ASPEN study evaluating its pipeline candidate brensocatib for the treatment of patients with bronchiectasis.

Zacks Equity Research

Insmed (INSM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -6.78% and -6.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -10.34% and 16.58%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Amgen (AMGN) Invests Further in China-Based Oncology Partner

by Zacks Equity Research

Amgen (AMGN) announces additional investment of approximately $421 million in BeiGene. The companies have a collaboration for oncology products signed in 2019.

Zacks Equity Research

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -10.45% and 9.20%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Insmed (INSM) Might Surprise This Earnings Season

by Zacks Equity Research

Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -1.72% and 0.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Company News for Feb 4, 2020

by Zacks Equity Research

Companies in the news are: GILD, MAXR, INSM, ABG

Zacks Equity Research

Insmed (INSM) in Focus: Stock Moves 7.1% Higher

by Zacks Equity Research

Insmed (INSM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Zacks Equity Research

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -3.03% and 12.20%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?